CSL Behring News
CSL Delivers Net Profit of Over $2.1 Billion
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a reported net profit after tax of $2,103 million (1) for the 12 months en…
Careful Steps Into a New Normal
One of CSL Behring's newest innovation centers in Bern, Switzerland, springs back to full life, with COVID-19 precautions in …
Bern's contribution against COVID-19
CSL Behring in Bern manufactures the hyperimmune for the pivotal Phase III clinical trial.
In Fight Against COVID-19
CSL Behring now evaluating 5 approaches to preventing and treating COVID-19.
Get a Look Inside Protinus
CSL Behring in Bern has made major progress on a large expansion project Protinus at its manufacturing facility.